Skip to main content
. 2010 Aug 25;5(8):e12400. doi: 10.1371/journal.pone.0012400

Figure 1. EAE +PTx icv mice developed an attenuated and delayed course of EAE.

Figure 1

Clinical scores were evaluated daily in EAE +PTx icv and control mice and were plotted as the mean ± S.D (n = 12/group). Maximum clinical scores as well as scores on day 14 and 23 evidence marked attenuation of disease severity after PTx icv (P<0.01). A dose response to PTx icv is demonstrated as well. Mice receiving lower doses of PTx icv (400 ng and 200 ng) continued to manifest a dose dependent benefit compared to the EAE controls (P<0.05).